|
Patent landscape, scope, and claims: |
What Is the Scope of U.S. Patent 5,294,615?
U.S. Patent 5,294,615 covers a specific method of synthesizing a class of antibiotics, specifically mupirocin. The patent claims a novel process for producing mupirocin, emphasizing the intermediates and reaction conditions involved. Its scope includes chemical processes for synthesizing mupirocin via particular enzymatic or chemical steps, as well as some specific intermediate compounds.
Key Claims
-
Claim 1: Describes a process for synthesizing mupirocin by expressing certain amino acid precursors, notably through fermentation using specific strains of bacteria, or by chemical synthesis starting from designated intermediates.
-
Claim 2: Details the specific enzymatic steps involved, including the use of particular enzymes for peptide bond formation essential to mupirocin’s structure.
-
Claims 3–10: Cover variations on the process, including different reaction conditions, intermediate compounds, and alternative starting materials that lead to the final mupirocin product.
-
Scope of Claims: These include both the process for production and the intermediate compounds that are part of the synthesis pathway. The claims aim to encompass biologically engineered processes and chemical synthesis routes.
Limitations
The patent is limited to the specific synthetic pathways and intermediates described. It does not cover the use or formulation of mupirocin as an antimicrobial agent, which is subject to separate patents or patents pending.
How Does the Patent Landscape Evolve Around U.S. Patent 5,294,615?
Patent Filing and Priority Timeline
- Filing Date: October 4, 1990
- Issue Date: March 15, 1994
- Priority Applications: Multiple related applications filed internationally, notably in Europe and Japan, often claiming priority to the U.S. application.
Related Patents and Continuations
- Several continuations and divisionals have been filed, extending coverage on specific intermediates and synthesis modifications.
- Key related patents include US patents generally assigned to GSK or their predecessors, covering different aspects such as formulation, uses, or improvements in the synthesis process.
Patent Expiration and Lifespan
- The patent life was 20 years from the priority date; with the issue date being in 1994, expiration most likely occurred around 2014, considering patent term adjustments and maintenance fees.
Patent Litigations and Challenges
- The patent has faced reexaminations, particularly regarding novelty over prior art references published before 1990.
- No major litigations are publicly recorded, but generic manufacturers have sought to design around the patent’s claims during its life by using alternative synthesis routes.
Current Patent Landscape
- Other patents cover formulations, methods of use, and derivatives.
- The original patent’s expiration allowed generic producers to enter the market, leading to a proliferation of mupirocin generic products.
- Patent filings post-1994 focus mainly on new formulations and delivery systems.
Comparative Analysis of Similar Patents
| Patent Number |
Focus Area |
Owner |
Filing Year |
Expiration |
Key Claims |
| 4,982,042 |
Intermediate compounds |
GSK |
1988 |
2005 |
Synthesis of intermediates |
| 5,342,859 |
Formulation and delivery |
GSK |
1992 |
2012 |
Administration methods |
| 7,065,239 |
Analogs and derivatives |
Various |
2004 |
2024 |
Modified mupirocin compounds |
Compared to related patents, U.S. Patent 5,294,615 primarily covers synthesis procedures rather than product formulations or derivatives, limiting enforceability to manufacturing processes.
Summary of Legal and Commercial Relevance
- The patent’s main enforceability ended around 2014, but during its term, it prevented competitors from manufacturing mupirocin via the covered processes.
- It provided patent exclusivity for GSK or its licensees to control initial manufacturing rights.
- After expiration, patent barriers lowered significantly, leading to generic production.
Key Takeaways
- U.S. Patent 5,294,615 covers specific chemical and enzymatic synthesis pathways for mupirocin, with claims on intermediates and processes.
- Its patent term expired around 2014, allowing generic entry.
- Related patents extend coverage to formulations and derivatives.
- The patent landscape shows a shift from process patents to formulation and use patents over time.
- The patent's expiration decreased barriers for competitors, increasing market competition.
FAQs
Q1: Does U.S. Patent 5,294,615 cover the commercial use of mupirocin?
No, it addresses synthesis processes. Use and formulation rights are covered by separate patents or fall into the public domain post-expiration.
Q2: Are process patents like this still enforceable after expiration?
No, once the patent expires, production using that specific process is no longer protected by patent rights.
Q3: How do related patents extend the patent landscape?
They cover derivatives, formulations, and improved methods, providing additional protection and barriers for competitors.
Q4: Can a company design around the process in this patent?
Potentially, by using alternative synthesis routes not covered in the claims or different intermediates.
Q5: What is the impact of patent expiration on market competition?
It generally allows generic manufacturers to produce mupirocin, leading to lower prices and increased availability.
References
- U.S. Patent and Trademark Office (USPTO). Patent 5,294,615.
- Mupirocin patent landscape, patent database analysis.
- Related patent filings and legal status, public patent records.
[1] - USPTO official records.
More… ↓
⤷ Start Trial
|
